AKT1 and gastric cancer: Therefore, the aim of this study is to determine if Tempol exerts anti-cancer activity in HT29 colon and CRL-1739 gastric cancer cells through the induction of apoptosis and oxidative stress and the suppression of MAPK and Akt/mTOR signaling pathways.